Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 16;11(12):1549.
doi: 10.3390/pathogens11121549.

A Comparison of Doxycycline and Amoxicillin Containing Quadruple Eradication Therapy for Treating Helicobacter pylori-Infected Duodenal Ulcers: A Multicenter, Opened, Randomized Controlled Trial in China

Affiliations

A Comparison of Doxycycline and Amoxicillin Containing Quadruple Eradication Therapy for Treating Helicobacter pylori-Infected Duodenal Ulcers: A Multicenter, Opened, Randomized Controlled Trial in China

Jingshu Chi et al. Pathogens. .

Abstract

Background: Increased antibiotic resistance is one of the major factors contributing to the failure of H. pylori eradication. This study aimed to compare the efficacy and safety of doxycycline and amoxicillin, both critical components for bismuth-based quadruple therapy, for the first-line treatment of H. pylori-infected duodenal ulcers. Methods: An open, randomized case-controlled, multicenter trial was conducted in seven hospitals in China. A total of 184 eligible participants were divided into an IDFB (ilaprazole 5 mg, doxycycline 100 mg, furazolidone 100 mg, and bismuth 220 mg bid) or IAFB (ilaprazole 5 mg, amoxicillin 1000 mg, furazolidone 100 mg, and bismuth 220 mg bid) group for 14 days. Both groups were administrated with ilaprazole 5 mg qd for another 14 days. The main outcome was an H. pylori eradication rate; secondary outcomes were ulcer healing, relief of symptoms, and incidence of adverse effects. Results: The H. pylori eradication rates were 85.9% (95% CI 78.6−93.9) in the IDFB vs. 84.8% (95% CI 77.3−92.3) in the IAFB group in ITT analysis (p > 0.05), and 92.9% (95% CI 87.4−98.5) vs. and 91.8% (95% CI 85.8−97.7) in PP analysis (p > 0.05). The overall ulcer healing rates of IDFB and IAFB were 79.1% and 84.7% (p > 0.05), both effective in relieving symptoms. Only nine participants had adverse reactions in this trial (4/92 in IDFB and 5/92 in IAFB). Conclusion: A bismuth quadruple regimen containing doxycycline or amoxicillin could be an effective and safe treatment for H. pylori eradication, while doxycycline replacement is an alternative for participants with penicillin allergy.

Keywords: Helicobacter pylori; antibiotic resistance; doxycycline; eradication; penicillin allergy; safety.

PubMed Disclaimer

Conflict of interest statement

All authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Study flow chart. Baseline data concerning age, sex, vital signs, and history of the study population were analyzed. No statistical difference was found between the two groups (p > 0.05, Table 1).

Similar articles

Cited by

References

    1. Mezmale L., Coelho L.G., Bordin D., Leja M. Review: Epidemiology of Helicobacter pylori. Helicobacter. 2020;25((Suppl. 1)):e12734. doi: 10.1111/hel.12734. - DOI - PubMed
    1. Ford A.C., Forman D., Hunt R.H., Yuan Y., Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: Systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g3174. doi: 10.1136/bmj.g3174. - DOI - PMC - PubMed
    1. Sonnenberg A., Turner K.O., Genta R.M. Low Prevalence of Helicobacter pylori-Positive Peptic Ulcers in Private Outpatient Endoscopy Centers in the United States. Am. J. Gastroenterol. 2020;115:244–250. doi: 10.14309/ajg.0000000000000517. - DOI - PubMed
    1. Kato M., Ota H., Okuda M., Kikuchi S., Satoh K., Shimoyama T., Suzuki H., Handa O., Furuta T., Mabe K., et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition. Helicobacter. 2019;24:e12597. doi: 10.1111/hel.12597. - DOI - PubMed
    1. El-Serag H.B., Kao J.Y., Kanwal F., Gilger M., LoVecchio F., Moss S.F., Crowe S.E., Elfant A., Haas T., Hapke R.J., et al. Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States. Clin. Gastroenterol. Hepatol. 2018;16:992–1002.e6. doi: 10.1016/j.cgh.2018.03.013. - DOI - PMC - PubMed

LinkOut - more resources